Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
European Journal of Medicinal Chemistry
|
October 15, 2022
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
Marilia Barreca, Virginia Spanò, Roberta Rocca, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
Molecular Cancer Therapeutics
|
February 7, 2024
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, et al.
Haematologica
|
February 9, 2019
The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
Stuart W Hicks, Chiara Tarantelli, Alan Wilhem, et al.
Blood Advances
|
March 4, 2020
Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models
Chiara Tarantelli, Martin Lange, Eugenio Gaudio, et al.
European Journal of Medicinal Chemistry
|
October 15, 2022
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
Marilia Barreca, Virginia Spanò, Roberta Rocca, et al.
Haematologica
|
June 19, 2025
Novel PI3kδ inhibitor roginolisib synergizes with venetoclax in hematologic malignancies
Binu Kandathilparambil Sasi, Chiara Tarantelli, Stephen Martindale, et al.
Biorxiv : the Preprint Server for Biology
|
November 28, 2023
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine
Alberto J Arribas, Eugenio Gaudio, Sara Napoli, et al.
Haematologica
|
December 15, 2018
New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease
Luca Aresu, Serena Ferraresso, Laura Marconato, et al.
Blood Advances
|
October 7, 2024
PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas
Alberto J Arribas, Sara Napoli, Eugenio Gaudio, et al.
Haematologica
|
May 9, 2024
Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
Chiara Tarantelli, David Wald, Nicolas Munz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 12, 2019
The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Filippo Spriano, Elaine Yee Lin Chung, Eugenio Gaudio, et al.
Page
of 6